Fenofi brate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels

Journal of Lipid Research

Volumn 51, Issue 2, 2010, Pages 345-351

  Troutt, Jason S ^a   Alborn, William E ^a   Cao, Guoqing ^a   Konrad, Robert J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Fi brates; HDL cholesterol; LDL receptor; LDL cholesterol; PCSK9

Indexed keywords

FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 PROTEIN; SERINE PROTEINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DYSLIPIDEMIA; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; MIDDLE AGED;

CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROCETOFEN; SERINE ENDOPEPTIDASES; TRIGLYCERIDES;

EID: 77949525476     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M000620     Document Type: Article

References (38)

1. Cao, G., Y. W. Qian, M. C. Kowala, and R. J. Konrad. 2008. Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease. Endocr. Metab. Immune Disord. Drug Targets. 8: 238-243.
2. Horton, J. D., J. C. Cohen, and H. H. Hobbs. 2007. Molecular biol-ogy of PCSK9: its role in LDL metabolism. Trends Biochem. Sci. 32: 71-77.
3. Qian, Y. W., R. J. Schmidt, Y. Zhang, S. Chu, A. Lin, H. Wang, X. Wang, T. P. Beyer, W. R. Bensch, W. Li, et al. 2007. Secreted pro-protein convertase subtilisin/kexin-type 9 reduces low-density lipo-protein receptor through receptor-mediated endocytosis. J. Lipid Res. 48: 1488-1498.
4. Lambert, G., M. Krempf, and P. Costet. 2006. PCSK9: a promising therapeutic target for dyslipidemias. Trends Endocrinol. Metab. 17: 79-81.
5. Graham, M. J., K. M. Lemonidis, C. P. Whipple, A. Subramaniam, B. P. Monia, S. T. Crooke, and R. M. Crooke. 2007. Antisense inhibition of proprotein convertase subtilisin kexin 9 reduces serum LDL in hyperlipidemic mice. J. Lipid Res. 48: 763-767.
6. Lagace, T. A., D. E. Curtis, R. Garuti, M. C. McNutt, S. W. Park, H. B. Prather, N. N. Anderson, Y. K. Ho, R. E. Hammer, and J. D. Horton. 2006. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J. Clin. Invest. 116: 2995-3005.
7. Maxwell, K. N., E. A. Fisher, and J. L. Breslow. 2005. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc. Natl. Acad. Sci. USA. 102: 2069-2074.
8. Park, S. W., Y. A. Moon, and J. D. Horton. 2004. Post-transcriptional regulation of low density lipoprotein receptor protein by propro-tein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 279: 50630-50638.
9. Benjannet, S., D. Rhainds, R. Essalmani, J. Mayne, L. Wickham, W. Jin, M. C. Asselin, J. Hamelin, M. Varret, D. Allard, et al. 2004. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279: 48865-48875.
10. Maxwell, K. N., and J. L. Breslow. 2004. Adenoviral-mediated expres-sion of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. USA. 101: 7100-7105.
11. Schmidt, R. J., T. P. Beyer, W. R. Bensch, Y. W. Qian, A. Lin, M. Kowala, W. E. Alborn, R. J. Konrad, and G. Cao. 2008. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem. Biophys. Res. Commun. 370: 634-640.
12. Li, J., C. Tumanut, J. A. Gavigan, W. J. Huang, E. N. Hampton, R. Tumanut, K. F. Suen, J. W. Trauger, G. Spraggon, S. A. Lesley, et al. 2007. Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem. J. 406: 203-207.
13. McNutt, M. C., T. A. Lagace, and J. D. Horton. 2007. Catalytic activ-ity is not required for secreted PCSK9 to reduce low density lipo-protein receptors in HepG2 cells. J. Biol. Chem. 282: 20799-20803.
14. Zhang, D. W., T. A. Lagace, R. Garuti, Z. Zhao, M. McDonald, J. D. Horton, J. C. Cohen, and H. H. Hobbs. 2007. Binding of pro-protein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 282: 18602-18612.
15. Chan, J. C., D. E. Piper, Q. Cao, D. Liu, C. King, W. Wang, J. Tang, Q. Liu, J. Higbee, Z. Xia, et al. 2009. A proprotein convertase subtil-isin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl. Acad. Sci. USA. 106: 9820-9825.
16. McNutt, M. C., H. J. Kwon, C. Chen, J. R. Chen, J. D. Horton, and T. A. Lagace. 2009. Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J. Biol. Chem. 284: 10561-10570.
17. Duff, C. J., M. J. Scott, I. T. Kirby, S. E. Hutchinson, S. L. Martin, and N. M. Hooper. 2009. Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem. J. 419: 577-584.
18. Maxwell, K. N., and J. L. Breslow. 2005. Proprotein convertase sub-tilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia. Curr. Opin. Lipidol. 16: 167-172.
19. Dubuc, G., A. Chamberland, H. Wassef, J. Davignon, N. G. Seidah, L. Bernier, and A. Prat. 2004. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regu-lated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24: 1454-1459.
20. Abifadel, M., M. Varret, J. P. Rabes, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, et al. 2003. Mutations in PCSK9 cause autosomal dominant hypercholes-terolemia. Nat. Genet. 34: 154-156. (Pubitemid 36666925)
21. Allard, D., S. Amsellem, M. Abifadel, M. Trillard, M. Devillers, G. Luc, M. Krempf, Y. Reznik, J. P. Girardet, A. Fredenrich, et al. 2005. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum. Mutat. 26: 497. 22
22. Cohen, J. C., E. Boerwinkle, T. H. Mosley, Jr., and H. H. Hobbs. 2006. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354: 1264-1272.
23. Fasano, T., A. B. Cefalu, E. Di Leo, D. Noto, D. Pollaccia, L. Bocchi, V. Valenti, R. Bonardi, O. Guardamagna, M. Averna, et al. 2007. A novel loss-of-function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol. Arterioscler Thromb. Vasc. Biol. 27: 677-681.
24. Zhao, Z., Y. Tuakli-Wosornu, T. A. Lagace, L. Kinch, N. V. Grishin, J. D. Horton, J. C. Cohen, and H. H. Hobbs. 2006. Molecular characterization of loss-of-function mutations in PCSK9 and identifi cation of a compound heterozygote. Am. J. Hum. Genet. 79: 514-523.
25. Rashid, S., D. E. Curtis, R. Garuti, N. N. Anderson, Y. Bashmakov, YK Ho, R. E. Hammer, Y A. Moon, and J. D. Horton. 2005
26. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. USA. 102: 5374-5379.
27. Berge, K E., L. Ose, and T. P. Leren. 2006. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler. Thromb. Vasc. Biol. 26: 1094-1100.
28. Alborn, W. E., G. Cao, H. E. Careskey, Y W. Qian, D. R Subramaniam, J. Davies, E. M. Conner, and R. J. Konrad. 2007. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin. Chem. 53: 1814-1819.
29. Careskey, H. E., R. A. Davis, W. E. Alborn, J. S. Troutt, G. Cao, and R J. Konrad. 2008. Atorvastatin increases human serum levels of pro-protein convertase subtilisin/kexin type 9. J. Lipid Res. 49: 394-398.
30. Dubuc, G., M. Tremblay, G. Pare, H. Jacques, J. Hamelin, S. Benjannet, L. Boulet, J. Genest, L. Bernier, N. G. Seidah, et al. 2009. A new method for measurement of total plasma PSCK9-clinical applications. J. Lipid Res.; Epub ahead of print.
31. Lakoski, S. G., T. A. Lagace, J. C. Cohen, J. D. Horton, and H. H. Hobbs. 2009. Genetic and metabolic determinants of plasma PCSK9 levels. J. Clin. Endocrinol. Metab. 94: 2537-2543.
32. Nissen, S. E., S. J. Nicholls, K Wolski, D. C. Howey, E. McErlean, M. D. Wang, E. V. Gomez, and J. M. Russo. 2007. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA. 297: 1362-1373.
33. Mayne, J., T. Dewpura, A. Raymond, M. Cousins, A. Chaplin, K A. Lahey, S. A. Lahaye, M. Mbikay, T. C. Ooi, and M. Chrétien. 2008. Plasma PCSK9 levels are signifi cantly modifi ed by statins and fi brates in humans. Lipids Health Dis. 7: 22-2 9.
34. Kourimate, S., C. Le May, C. Langhi, A. L. Jarnoux, K Ouguerram, YZaïr, P. Nguyen, M. Krempf, B. Cariou, and P. Costet. 2008. Dual mechanisms for the fi brate-mediated repression of proprotein con vertase subtilisin/kexin type 9. J. Biol. Chem. 283: 9666-9673.
35. Lambert, G., N. Ancellin, F. Charlton, D. Comas, J. Pilot, A. Keech, S. Patel, D. R. Sullivan, J. S. Cohn, K A. Rye, et al. 2008. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofi brate treatment. Clin. Chem. 54: 1038-1045.
36. Farnier, M. 2008. Update on the clinical utility of fenofi brate in mixed dyslipidemias: mechanisms of action and rational prescribing. Vasc. Health Risk Manag. 4: 991-1000.
37. Keating, G. M., and K F. Croom. 2007. Fenofi brate. A review of its use in primary dyslipidemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs. 67: 121-153.
38. Paumelle, R., and B. Staels. 2008. Cross-talk between statins and PPARa in cardiovascular diseases: clinical evidence and basic mechanisms. Trends Cardiovasc. Med. 18: 73-78.